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Articles
Microneedle biosensors for real-time, minimally invasive drug 
monitoring of phenoxymethylpenicillin: a first-in-human 
evaluation in healthy volunteers
Timothy M Rawson, Sally A N Gowers, David M E Freeman, Richard C Wilson, Sanjiv Sharma, Mark Gilchrist, Alasdair MacGowan, 
Andrew Lovering, Mark Bayliss, Mathew Kyriakides, Pantelis Georgiou, Anthony E G Cass, Danny O’Hare, Alison H Holmes
Summary
Background Enhanced methods of drug monitoring are required to support the individualisation of antibiotic dosing. 
We report the first-in-human evaluation of real-time phenoxymethylpenicillin monitoring using a minimally invasive 
microneedle-based β-lactam biosensor in healthy volunteers.
Methods This first-in-human, proof-of-concept study was done at the National Institute of Health Research/Wellcome 
Trust Imperial Clinical Research Facility (Imperial College London, London, UK). The study was approved by London-
Harrow Regional Ethics Committee. Volunteers were identified through emails sent to a healthy volunteer database 
from the Imperial College Clinical Research Facility. Volunteers, who had to be older than 18 years, were excluded if they 
had evidence of active infection, allergies to penicillin, were at high risk of skin infection, or presented with anaemia 
during screening. Participants wore a solid microneedle β-lactam biosensor for up to 6 h while being dosed at steady 
state with oral phenoxymethylpenicillin (five 500 mg doses every 6 h). On arrival at the study centre, two microneedle 
sensors were applied to the participant’s forearm. Blood samples (via cannula, at –30, 0, 10, 20, 30, 45, 60, 90, 120, 150, 
180, 210, 240 min) and extracellular fluid (ECF; via microdialysis, every 15 min) pharmacokinetic (PK) samples were 
taken during one dosing interval. Phenoxymethylpenicillin concentration data obtained from the microneedles were 
calibrated using locally estimated scatter plot smoothing and compared with free-blood and microdialysis (gold 
standard) data. Phenoxymethylpenicillin PK for each method was evaluated using non-compartmental analysis. Area 
under the concentration–time curve (AUC), maximum concentration, and time to maximum concentration were 
compared. Bias and limits of agreement were investigated with Bland–Altman plots. Microneedle biosensor limits of 
detection were estimated. The study was registered with ClinicalTrials.gov, number NCT03847610.
Findings Ten healthy volunteers participated in the study. Mean age was 42 years (SD 14). Seven (70%) were men. 
Microdialysis and microneedle results were similar for phenoxymethylpenicillin ECF maximum concentration 
(0·74 mg/L vs 0·64 mg/L; 95% CI –0·24 to 0·44; p=0·53), time to maximum concentration (1·18 h vs 1·10 h; 
–0·52 to 0·67; p=0·79), and AUC (1·54 mg × h/L vs 1·67 mg × h/L; –1·10 to 0·85; p=0·79). In total, 440 time points 
were compared with mean difference between measurements –0·16 mg/L (95% CI –1·30 to 0·82). Mean 
phenoxymethylpenicillin AUCs for free serum and microneedle PK were similar (1·77 mg × h/L [SD 0·59] vs 
1·67 mg × h/L [1·00]; –0·77 to 0·97; p=0·81). Median coefficient of variation between sensors within individuals was 
7% (IQR 4–17). Limit of detection for the microneedles was estimated at 0·17 mg/L.
Interpretation This study is proof-of-concept of real-time, microneedle sensing of penicillin in vivo. Future work will 
explore microneedle use in patient populations, their role in data generation to inform dosing recommendations, and 
their incorporation into closed-loop control systems for automated drug delivery.
Funding: National Institute for Health Research Imperial Biomedical Research Centre, Mérieux Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Individualised approaches to drug monitoring can en­
hance antimicrobial dosing and the treatment of infect­
ion. Individualised dosing improves clinical outcomes, 
while minimising the adverse consequences of anti­
micro bial therapy, especially development of toxicity and 
antimicro bial resistance (AMR).1 AMR poses a global 
threat to human health.2,3 A major modifiable driver of 
AMR is suboptimal dosing of antibiotics.2 The well 
reported observation of wide variations in individual 
pharmacokinetic (PK)–pharmaco dynamic target attain­
ment has highlighted the need for enhanced methods 
of drug monitoring to facilitate individualised dose 
optimisation.4,5
Therapeutic drug monitoring is a cornerstone of indi­
vidual dose optimisation. However, commercial assays 
are only available for a handful of antibiotics, target­
ing drugs with a narrow therapeutic index, such as 
vancomycin—a glycopeptide antibiotic—and the amino­
glycosides. Therapeutic drug monitoring for these drugs 
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is crucial for preventing toxicity. The use of thera­
peutic drug monitoring for individualised dosing of anti­
biotics, such as the β­lactams, can improve clinical 
outcomes.1,6 Current methods of therapeutic drug mon­
itoring for individualised antibiotic dosing present 
operational and technical barriers.5,7 To address these 
issues, the develop ment of wearable, real­time biosensor 
technology that can be deployed in a minimally invasive 
fashion and deliver continuous drug monitoring has 
been proposed.4
Microneedle technology has been under development 
for the past 20 years.8 To date, the majority of applications 
for microneedles involve drug and vaccine delivery.8 
However, hollow microneedle arrays have been designed 
to perform microsampling of extracellular fluid (ECF) to 
facilitate analysis ex vivo.9,10 This approach has similar 
analytical problems (eg, the need to extract ECF and 
ex­vivo analysis) as alternative approaches, such as micro­
dialysis and therefore cannot be used to facilitate real­time 
drug monitoring. In contrast, solid microneedle arrays 
have been used for continuous monitoring of glucose and 
lactate directly in dermal ECF.11–14 Therefore, it might also 
be possible to use this type of technology to monitor ECF 
antibiotic concentrations in humans.4,15
This study is a first in­human exploration of a β­lactam 
microneedle array biosensor for the monitoring of 
phenoxymethylpenicillin, a commonly used antibiotic, in 
healthy volunteers.15 It aimed to show the reliability and 
potential of a minimally invasive microneedle array bio­
sensor for continuous drug monitoring. The secondary 
objectives of the study were to explore the accuracy of the 
microneedle sensors against current gold standards of 
drug monitoring (ie, blood sampling via cannula and 
ECF concentrations using microdialysis). Tolerability 
of wearing the microneedle array was compared with 
cannula and microdialysis catheter insertion using visual 
analogue scales.
Methods
Study design
This study was a first­in­human, proof­of­concept study to 
evaluate the ability of microneedle biosensors to do real­
time drug monitoring in healthy volunteers. The study was 
done at the National Institute of Health Research/Wellcome 
Trust Imperial Clinical Research Facility (Imperial College 
London, London, UK).
The study protocol was reviewed and approved by 
London­Harrow Regional Ethics Committee. 
Participants
Between April and August, 2018, participants were 
identified through emails sent to a healthy volunteer 
database containing over 2000 potential volunteers, held 
at Imperial College Clinical Research Facility. Male and 
female healthy volunteers older than 18 years were elig­
ible for inclusion. Volunteers were excluded if they had 
evidence of active infection, allergies to phenoxymethyl­
penicillin, were at high risk of skin infection (eg, atopic 
dermatitis) near the sensor site, or presented with anaemia 
(defined as haemoglobin <13 g/dL for men and <12 g/dL 
for women) during screening. If volunteers responded to 
the advertisement, they were initially screened via email 
followed by a screening visit at the Clinical Research 
Facility. Those meeting study criteria at screening were 
invited to participate in the study. All participants provided 
written, informed consent.
Research in context
Evidence before the study
We searched PubMed, Web of Science, and Google Scholar, from 
inception to May 24, 2019, for studies reporting methods for 
real-time antibiotic drug monitoring, using main search terms 
“drug monitoring”, “antibiotic”, “real-time”, and “continuous”. 
We only considered original research and review articles 
published in English. Although several biosensor and 
microneedle technologies have been reported in the literature, 
no in-human studies have been done to our knowledge. Invasive 
techniques, using biosensors mounted on central venous 
catheters inserted into ambulatory rodents have previously been 
described. Hollow microneedle technologies have been reported 
and tested in vitro; however, these technologies do not provide 
true in-vivo monitoring potential because of the requirement for 
extracellular fluid extraction via microsampling. Solid 
microneedle arrays have been used to show real-time glucose 
monitoring in healthy volunteers and patients with diabetes in 
proof-of-concept studies, suggesting that solid microneedle 
array antibiotic biosensors could potentially provide real-time, 
in-vivo antibiotic drug monitoring.
Added value of the study
This first-in-human study provides proof-of-concept that a 
minimally invasive, microneedle β-lactamase biosensors can be 
used for real-time, in-vivo antibiotic drug monitoring. 
This study provides evidence to support the wider exploration 
of microneedle antibiotic monitoring in patients and for a 
broader range of antimicrobial drugs. It is also the first 
step towards automated, individualised antibiotic dosing 
in humans through the application of closed-loop 
control systems.
Implications of all the available evidence
As well as supporting future exploration of real-time antibiotic 
monitoring, this study adds to the growing body of literature 
showing proof-of-concept for direct in-vivo monitoring of 
drugs using solid microneedle array biosensors. The 
implications of this research extend beyond antibiotics and 
even drugs, also providing evidence for biomarker monitoring 
in vivo using solid microneedle arrays. 
Articles
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Procedures
Healthy volunteers were recruited to wear a microneedle 
β­lactam biosensor for up to 6 h while being dosed 
at steady state with oral phenoxymethylpenicillin. Oral 
phenoxy methylpenicillin was the β­lactam chosen because 
of its convenience (ie, it can be delivered orally rather than 
by injection), well documented safety profile, and narrow 
spectrum of activity. Participants took five doses of 
phenoxymethyl penicillin (500 mg every 6 h, a standard 
treatment dose for bacterial infections in adults) on an 
empty stomach before attending the study, documenting 
doses on a self­reported diary card.
On arrival at the study centre, two microneedle sensors 
were applied to the participant’s forearm. A cannula for 
blood sampling was inserted in a large vein in the 
antecubital fossa. A microdialysis catheter was inserted 
subcutaneously in the forearm close to the microneedle 
array. Participant baseline characteristics (height, weight, 
gender, age, and body­mass index [BMI]) were collected 
and glomerular filtration rate estimated using the 
Cockcroft­Gault equation. Participants were dosed on an 
empty stomach with 500 mg oral phenoxymethylpenicillin 
(ie, at time=0 min). The output from the microneedle array 
sensors was recorded for comparison to concomitant blood 
and tissue ECF PK samples. The blood and ECF samples 
were taken via a cannula and by microdialysis, respectively.
Microneedle biosensors
The development and in­vitro validation of the 
microneedle array biosensors used in this study have 
been described in detail.15,16 Figure 1 summarises the 
microneedle array structure and application process. The 
polycarbonate microneedle array structure is metallised 
to produce four independent electrodes. Each electrode 
is created by first metallising the electrode areas with an 
adhesion layer of chromium (110 nm). Three of the 
electrodes are then coated with gold (150 nm) to create 
independent working electrodes. The fourth electrode is 
metallised with 150 nm of silver and then chloridised 
to act as a silver–silver chloride reference electrode. 
The working electrodes are subsequently modified by 
electrodeposition of iridium oxide to measure changes in 
pH.15,16 Finally, a hydrogel layer containing an extended 
spectrum β­lactamase from Enterobacter cloacae (Sekisui 
Diagnostics, Tokyo, Japan) is added.15,16 Sterilisation is 
achieved with Colbalt­60 gamma radiation.
The sensors are applied to the forearm with firm 
pressure for 60 s and secured in place with a transparent 
medical dressing. The sensors are connected to a 
potentiostat and the open circuit potential of the working 
electrode versus the reference electrode recorded. As 
phenoxymethylpenicillin in the ECF diffuses into the 
hydrogel layer, it is hydrolysed to penicilloate and a 
proton by β­lactamase. Therefore, as the concentration 
of phenoxymethylpenicillin in the tissue increases, the 
concentration of protons generated at the sensor surface 
increases. This process leads to a fall in the local pH at 
the sensor surface, which is detected as an increase in 
open circuit potential as the equilibrium of iridium oxide 
oxidation states (ie, the ratio of iridium + 3 to iridium + 4) 
within the sensor is shifted. For calibration of the work­
ing electrodes, a control electrode is also worn. The 
control electrode is identical to the working electrode but 
without β­lactamase enzyme in the hydrogel layer. Its use 
provides a background potential that is subtracted from 
the working electrode potential to compensate for any 
Figure 1: Experimental setup 
(A) Microneedle base used for the study. (B) 20 μm cross-section of human skin after microneedle application stained with haematoxylin and eosin). 
Examination under microscope shows penetration of the microneedles through the epidermis. (C) Schematic of the penetration of the microneedle array into the 
dermal-interstitial space. (D) Application of a microneedle array biosensor to the forearm with firm pressure for 60 s. (E) Time lapse of marks left after wearing a 
microneedle for 6 h immediately after removal, 1 h after removal (F), and 12 h after removal (G).
PenicillinPenicilloate plus proton
Working electrode Reference electrodeCA
0·1 mm
B
D E F G
Articles
4 www.thelancet.com/digital-health   Published online September 30, 2019    https://doi.org/10.1016/S2589-7500(19)30131-1
time­dependent changes in the sensor output, which are 
independent of changes in analyte concentration (drift).
During the study period, each participant wore two 
microneedle devices. One containing working elec trodes 
and one containing the control electrode. The open cir­
cuit potential (in mV) was recorded 200 times every 
second for each electrode. This measurement provided 
data for three phenoxymethylpenicillin sensors and one 
control array per participant. The electrochemical signal 
was recorded with an in­house instrument for potentio­
metric recording of biosignals (Imperial College London, 
London, UK).17
Blood samples
A maximum of 15 blood samples were acquired before 
and after the final (sixth dose, time=0 min) dose of 
phenoxymethylpenicillin. Blood samples were taken via a 
cannula at times –30, 0, 10, 20, 30, 45, 60, 75, 90, 105, 120, 
150, 180, 210, and 240 min. Samples were allowed to clot 
for 10 min and then placed on ice. They were centrifuged 
(at 3000 G for 10 min) within 30 min. The serum 
was stored at –80°C until analysed. Analysis was done 
using high­performance liquid chromatography tandem 
mass spectrometry at Bristol Antimicrobial Reference 
Laboratory (Bristol, UK). Both total and free (unbound) 
drug concentrations were determined. Free antibiotic 
concentration was determined for individuals by perform­
ing ultrafiltration (Centrifree ultrafiltration, 30 kDa molec­
ular weight cutoff; Sigma­Aldrich, Schnelldorf, Germany). 
Each participant had free drug concentration determined 
at three collection timepoints and an average was calcu­
lated. The limit of quantification for the high­performance 
liquid chromatography tandem mass spectrometry assay 
was 0·10 mg/L.
Microdialysis
ECF phenoxymethylpenicillin concentrations were deter­
mined through continuous microdialysis. A microdialysis 
catheter (CMA 63 microdialysis catheter, 20 kDa molecular 
weight cutoff; Linton Instruments, Norfolk, UK) was 
inserted into the subcutaneous tissue of the forearm after 
application of topical local anaesthetic. The catheter 
was perfused using sterile T1 perfusion fluid (sodium 
147 mmol/L, potassium 4 mmol/L, calcium 2·3 mmol/L, 
chloride 156 mmol/L; Linton Instruments, Norfolk, UK) 
with a flucloxacillin internal standard (10 mg/L).18–20 The 
rate of perfusion was 2 µL/min with microvials changed 
every 15 min during the study period. The first 30 min 
was designated the equilibrium period with samples 
obtained during this period excluded from the analy­
sis. Microdialysis sampling commenced 1 h before 
phenoxymethylpenicillin administration (ie, time=0 min) 
and continued until the end of each study period 
(240 min). Microdialysis vials were stored at –80°C follow ­
ing collection until analysed. Analysis was done using 
high­performance liquid chromatography tandem mass 
spectrometry at Bristol Antimicrobial Research Centre 
(Bristol, UK). The limit of quantification for the phen­
oxymethylpenicillin and flucloxacillin assays were both 
0·10 mg/L.
In­vivo recovery of phenoxymethylpenicillin in the 
micro dialysate solution was determined from the meas­
ured loss of the flucloxacillin internal standard across the 
microdialysis membrane for individual participants: 
where Cin is the concentration of flucloxacillin meas ­
ured in the perfusate and Cout is the concentration of 
flucloxacillin measured in the microdialysate for each 
indi vidual volunteer. This in­vivo recovery was used to 
estim ate actual tissue ECF concentration from the 
dialysate concentration.
Outcomes
The primary outcome of this study was to determine 
whether a microneedle biosensor could be used to mon­
itor phenoxymethylpenicillin concentrations in human 
dermal ECF.
Data processing and analysis
Microneedle data, in mV, were recorded in real­time. All 
processing and calibration into phenoxymethylpenicillin 
concentration was done after data collection. Signal pro­
cessing was done by firstly subtracting the control sensor 
from individual working electrodes to correct back­
ground drift. Noise was corrected for using first order 
locally estimated scatterplot smoothing (LOESS) filters in 
IgorPro8 (WaveMetrics, Lake Oswego, OR, USA).
Given the study aims, the small number of sensors, and 
potential person­to­person and sensor­to­sensor variation, 
separate calibration and validation cohorts would be 
challenging. We chose to split individual sensor data into 
independent calibration and validation sets. To calibrate 
individual sensors, a random selection of time points 
were plotted against corresponding microdialysis data. 
For each individual sensor, a first order polynomial was 
determined by linear regression between sensor output 
and microdialysis tissue concentration. This polynomial 
was then used to convert sensor output (mV) to phenox­
ymethylpenicillin concentration (mg/L) in the validation 
dataset. Concentration data from all micro needle sensor 
validation sets were then compared with microdialysis 
results at corresponding timepoints using Bland­Altman 
plots to examine for bias and limits of agreement.
As calibration of the microneedles was based on regress­
ion of microdialysis results, the method of concentration 
determination for the microneedle arrays is not entirely 
independent of the microdialysis data. However, the 
purpose of Bland–Altman plot in this study was to show 
the methods are in agreement over the entire dataset 
using independent measurements of calibration and 
validation. Therefore, while considering this limitation, 
we agreed that this method of evaluation remained valid 
Percentage of penicillin recovery=100 × (Cin–mean Cout/Cin)
See Online for appendix
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for initial comparison of the microneedles against the 
current gold standard, microdialysis.
Limits of detection of the microneedle biosensors were 
estimated as: 
where Csd is the standard deviation of the y­intercept (C) 
of a first order polynomial generated by fitting a line of 
regression through the pooled microneedle array data and 
M represents the slope function for the same polynomial.21
Limit of quantification was estimated as:21 
The PK profiles of free serum, microdialysis, and 
micro needle data were determined and compared using 
non­compartmental analysis. This analysis was done with 
Pmetrics software, in R (R Core Development Team).22 
Figures were plotted using IgorPro8 to estimate the area 
under the concentration–time curve (AUC), maximum 
concentration (Cmax), and time to maximum concentra­
tion for each measurement method. Statistical analysis 
was done using t tests in R.
Visual analogue scoring
During the study visit, participants completed visual 
analogue scoring from 0 to 10 cm, rating pain or discomfort 
caused by cannula, microdialysis catheter, and the micro­
needles. Visual analogue scoring was collected immediately 
and 3 h after insertion. Mean scores were visually com­
pared. Statistical analysis was not done as it was not 
powered to account for type 2 errors.
The study was registered with ClinicalTrials.gov in 
February, 2019, number NCT03847610. Registration was 
delayed because of an administrative error during local 
registration that should have facilitated ISRCTN registra­
tion. The registered study protocol was not amended in 
anyway following ethics committee approval. The protocol 
is available in the appendix. 
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
Figure 2: Example of individual microneedle data calibration against blood 
and extracellular fluid penicillin concentrations
(A) Raw sensor data (mV) with the control sensor data subtracted. (B) Locally 
weighted scatter plot smoothing (LOESS) analysis of sensor data (mV).  (C) MN 
data converted to penicillin concentration (mg/L) using individual first order 
polynomial equations. Time=0 min when dose of 500 mg 
phenoxymethylpenicillin is administered to the patient. MN=microneedle. 
ECF=extracellular fluid. Ag=silver. Cl=chloride.
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decision to submit for publication. The views expressed 
in this publication are those of the authors and not nec­
essarily those of the National Health Service, the National 
Institute for Health Research, or the UK Department 
of Health.
Results
150 responses to the initial advertisement were received. 
Of these, 81 (54%) completed the email screening. Screen­
ing visits at the Clinical Research Facility were organised 
with 25 (31%) of 81 individuals. 17 (68%) were eligible for 
inclusion. Three (18%) of 17 withdrew after screening, 
and three were held on standby for the study. We had 
standby participants because we only needed to recruit 
ten participants in total and recruitment screening visits 
were staggered. In total, 11 (65%) volunteers participated 
in the study. One volunteer withdrew consent to undergo 
microdialysis on the study day and was withdrawn from 
the analysis. The participant did not cite a reason for 
declining microdialysis catheter insertion. Therefore, ten 
volunteers were included in the study.
The mean age of participants was 42 years (SD 14) and 
seven (70%) of ten participants were men. Participants 
mean height was 174 cm (11), weight 74 kg (15), and 
BMI 24 kg/m² (3). Mean creatinine clearance was 
114 mL/min (29).
Each participant wore a microneedle array containing 
three enzyme­coated sensors (30 sensors in total) and one 
array containing the control sensor (ten sensors in total). 
Data for 25 (83%) of 30 enzyme­coated sensors were 
available for analysis. In two cases (participant 1 and 5), 
one of the three working electrodes failed due to poor 
electrical connectivity. For participant 9, data from all 
three working electrodes became corrupted, meaning 
that data for this individual were not available for analysis.
Microneedle data were recorded for a mean of 
3·74 h (SD 0·48). A mean of 13 blood samples (SD 1) 
and 14 microdialysis PK samples (3) were taken per 
participant. Figure 2A shows raw microneedle data for the 
three microneedle arrays (mV) plotted against free serum 
and ECF phenoxymethylpenicillin concentration (mg/L). 
Figure 2B shows LOESS smoothing of the microneedle 
data and figure 2C shows final calib rated microneedle 
data (mg/L) against free serum and ECF (microdialy­
sis) determined phenoxymethyl penicillin concentrations. 
Table 1 describes the individual participant PK comparison 
of serum, microdialysis, and microneedle monitoring 
using non­compartmental analysis. Mean microdialysis 
recovery of phenoxymethyl penicillin was estimated at 
23% (SD 4; table 2). Concentration data obtained from 
the microneedle sensors were similar to that from 
Age 
(years)
Gender Unbound 
phenoxymethylpenicillin 
in serum (%)
Blood Microdialysis Microneedle
Cmax 
(mg/L)
Tmax 
(h)
AUC 
(mg x h/L)
Cmax 
(mg/L)
Tmax AUC 
(mg x h/L)
Cmax 
(mg/L)
Tmax 
(h)
Average AUC 
(mg x h/L)
1 56 Male 33 2·04 0·47 2·20 0·85 0·15 2·92 0·79 0·15 2·94
2 43 Male 21 0·99 1·28 1·63 0·37 1·46 0·87 0·37 1·29 1·09
3 30 Male 25 0·48 0·75 1·10 0·25 1·51 0·55 0·22 1·01 0·58
4 65 Male 23 1·60 0·75 2·07 0·81 0·93 1·27 0·54 1·19 1·29
5 51 Male 25 2·23 0·50 2·16 1·16 0·93 2·08 0·99 0·49 2·10
6 52 Male 23 0·65 0·88 1·27 1·33 1·56 2·84 1·07 2·34 3·71
7 28 Male 21 0·90 0·37 1·38 0·36 0·88 0·84 0·33 1·02 0·83
8 51 Female 16 0·90 0·55 1·16 0·61 1·96 0·95 0·58 1·71 0·88
9 23 Female 22 2·05 0·95 3·09 NA NA NA NA NA NA
10 23 Female 22 1·41 0·95 1·66 0·91 1·21 1·59 0·84 0·69 1·615
Mean (SD) 42 (14) ·· 23 (4) 1·32 (0·60) 0·75 (0·26) 1·77 (0·59) 0·74 (0·37) 1·18 (0·53) 1·54 (0·88) 0·64 (0·30) 1·10 (0·65) 1·67 (1·00)
Cmax=maximum concentration. Tmax=time to maximum concentration. AUC=area under the concentration–time curve. NA=data not available.
Table 1: Comparison of individual participant demographics and microneedle data
p value 95% CI
Free blood vs microneedle
Cmax (mg/L) 0·0095 0·21 to 1·17
Tmax (h) 0·16 –0·87 to 0·17
AUC (mg x h/L) 0·81 –0·77to 0·97
Free blood vs microdialysis
Cmax (mg/L) 0·025 0·08 to 1·09
Tmax (h) 0·049 –0·86 to –0·01
AUC (mg x h/L) 0·53 –0·53 to 0·98
Microneedle vs microdialysis
Cmax (mg/L) 0·53 –0·24 to 0·44
Tmax (h) 0·79 –0·52 to 0·67
AUC (mg x h/L) 0·79 –1·10 to 0·85
Cmax=maximum concentration. Tmax=time to maximum concentration. 
AUC=area under the concentration–time curve. 
Table 2: Statistical comparison of free blood, microneedle, and 
microdialysis pharmacokinetic parameters derived using 
non-compartmental analysis
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microdialysis (mean AUCs 1·67 mg × h/L [SD 1·00] for 
microneedle vs 1·54 mg      × h/L [0·88] for microdialysis; 
95% CI –1·10 to 0·85; p=0·79; tables 1, 2). Mean Cmax 
was also similar between measurements for both 
techniques (0·64 mg/L [0·30] vs 0·74 mg/L [0·37]; 
–0·24 to 0·44; p=0·53; tables 1, 2).
Overall, there was a good agreement with a mean 
difference between microneedle and microdialysis meas­
urements of –0·16 mg/L and the majority of points were 
within the 1·96 SD range (0·82 to –1·30; figure 3). 
Deviation beyond the 1·96 SD range can be attributed to 
a single individual’s microneedle array. Limit of detection 
was estimated at 0·17 mg/L and limit of quantification at 
0·55 mg/L. Median coefficient of variation (CV) between 
sensors for the same individual was 7% (IQR 4–17).
PK parameters for free serum phenoxymethylpenicillin 
concentration were compared with parameters deter­
mined using the microneedle biosensors. Phenoxy­
methylpenicillin protein binding was variable between 
individuals with a mean free phenoxymethylpenicillin 
fraction of 23% (SD 4; table 1; CV 18%). Free serum and 
microneedle PK had similar mean AUCs (1·77 mg × h/L 
[SD 0·59] for free serum vs 1·67 mg × h/L [1·00] for 
microneedle; 95% CI –0·77 to 0·97; p=0·81; tables 1, 2). 
Free serum Cmax was significantly higher than micro­
needle measurements of the ECF (1·32 mg/L [0·60] vs 
0·64 mg/L [0·30]; 0·21 to 1·17; p=0·0095; tables 1, 2).
All modalities of phenoxymethylpenicillin measure­
ment were well tolerated. Mean visual analogue scoring 
for microneedles, microdialysis catheter, and cannula was 
low. At insertion, microneedle pain or discomfort scored 
a mean of 0·9 cm (SD 1·5) falling to 0·1 cm (0·2) at 3 h. 
Cannula insertion scored 0·2 cm (0·2) on insertion rising 
to 0·5 cm (0·8) at 3 h. Microdialysis scored 1·5 cm (3) at 
insertion and 0 (0) at 3 h. No participants experienced any 
adverse events (data not shown).
Discussion
In this first­in­human evaluation of microneedle antibiotic 
drug monitoring, we showed that a microneedle β­lactam 
biosensor could monitor changes in ECF drug, could be 
calibrated to drug concentration, and was well tolerated by 
healthy volunteers. PK profiles of ECF phenoxymethyl­
penicillin were similar between micro dialysis and micro­
needle methods but showed highly variable PK between 
participants. AUCs of free antibiotic in serum and ECF 
were similar, but highly variable between participants. 
These results are in line with documented variability in the 
PK of phenoxymethylpenicillin.23
Real­time, minimally invasive, microneedle drug 
monitor ing provides the ability to monitor and poten­
tially react to changing drug PK within the individual and 
might support the development of individualised app­
roaches to antibiotic dosing. Within our study, microneedle 
bio sensors were calibrated against, and subsequently 
compared with, individual discrete tissue microdialysis 
measurements, which is the current gold standard for 
determining ECF drug concentration. Using this method, 
the microneedle biosensors had high concordance with 
microdialysis in terms of phenoxy methylpenicillin PK 
profile and determining ECF drug concentration, pro­
viding a proof­of­concept for their application in wider 
clinical practice. Table 3 compares potential benefits of 
microneedle versus microdialysis methods for ECF drug 
monitoring.15,18,24–26 Similarly, the potential benefit of micro­
needle technology over blood sampling is that no laboratory 
analytics are required, monitoring can be continuous, and 
the process is minimally invasive with no exposure to 
blood of other potential hazardous bodily fluids.9,10
Microneedle ECF antibiotic measurement might 
facilitate optimisation of other compartment drug con­
centrations in the future, including serum. Free (un­
bound) concentration of drug is the current gold standard, 
given that free drug is in equilibrium between body 
compartments, such as blood and ECF.27 Therefore, the 
development of minimally invasive microneedle sensors 
might provide a mechanism to guide blood compartment 
Figure 3: Bland-Altmann plot comparing agreement of ECF phenoxymethylpenicillin measurements between 
microdialysis and microneedle (A) and scatter plot for the estimation of lower limit of detection and lower 
limit of quantification for the microneedle biosensors (B)
ECF=extracellular fluid. LC-MS/MS=high-performance liquid chromatography tandem mass spectrometry.
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dose optimisation.4 This study supports this argument by 
showing similar AUCs in serum and ECF. Through the 
greater exploration of this technique and linkage to other 
drug compartments, dose optimisation might become 
a reality.
Several outstanding variables must now be explored, 
including the effect of conditions such as sepsis on 
ECF volume expansion and pH change, and the abil­
ity of microneedles to detect both subtherapeutic and 
supratherapeutic drug concentrations accurately. Based 
on preliminary in­vitro analysis and data from this 
study, we anticipate that the microneedle biosensors 
should perform within appropriate limits of detection.15,16 
Further more, the use of a control sensor allows for 
changes in individual ECF pH to be controlled for in the 
calibration step.15,16 Finally, microdialysis studies already 
provide data showing PK variability within ECF in critical 
illness. Given the variable PK of phenoxymethylpenicillin 
in ECF, this study provides initial evidence to support the 
appropriateness of microneedles to cope with wide ECF 
variations in sepsis.
The current study aimed to show the potential of 
microneedle sensors through calibration against indi­
vidual microdialysis data. However, for wider roll out and 
evaluation when microdialysis is not available, alternative 
standardised calibration techniques are required. This 
process might be achieved through concurrent free drug 
analysis of serum allowing estimation and comparison of 
AUCs between com partments, or through standardised 
calibration of devices based on pooled data. Furthermore, 
the enzyme­based biosensor used in this study might not 
be appropriate for all antibiotics, such as aminoglyco­
sides, or in the presence of enzyme inhibitors, such 
as amoxicillin–clavulanic acid or piperacillin–tazobactam 
drug combinations.4 The selection and functionalisation of 
aptamer technology has already been shown to be possible 
for real­time drug monitoring and offers an alternative 
sensing modality for application to microneedles.28,29 Fin­
ally, the combination of microneedle sensing with methods 
of individualised antibiotic dosing, such as closed­loop 
control systems, is yet to be shown in vivo.4,30
The current study also has several limitations. This 
study was done in healthy volunteers using an orally 
administered phenoxymethylpenicillin designed to show 
proof of concept for real­time, minimally invasive mon­
itoring of antibiotics in humans. Drug PK, especially in 
ECF, was highly variable between individuals making 
grouped sensor analysis challenging. Data from five (16%) 
of 30 microneedle electrodes were not available for 
analysis. Furthermore, the study of healthy volunteers 
makes generalisability to patients challenging, particularly 
in reference to changes that occur in sepsis and with 
polypharmacy. This study does, however, provide proof­
of­concept for microneedle­based antibiotic therapeutic 
drug monitoring and will be further explored in patient 
populations now that the safety and potential reliability of 
such technology has been shown in vivo.
In conclusion, this first­in­human study of microneedle 
array biosensors for antibiotic therapeutic drug monitoring 
has shown that minimally invasive, microneedle sensors 
are able to continuously monitor ECF antibiotic concen­
trations in line with current microdialysis gold standards. 
The microneedle results showed similar free drug AUC 
when compared with serum AUC. The PK profiles were 
also similar between microneedle and microdialysis 
methods of ECF monitoring, with highly variable PK. 
Further work will explore the role of these sensors in 
obtaining necessary data to optimise β­lactam dosing 
in patient populations and as part of real­time dose 
optimisation using closed­loop control systems.
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Microneedles Microdialysis
Disruption to local tissue Minimal evidence of local 
tissue disruption
Potential for disruption of local tissues, 
inflammation, and bleeding during 
insertion18
Practicality for use in clinical 
practice
Easy application, no needles or 
skin puncture required
Requires training and puncture of the skin
In-vivo measurement Direct detection in vivo Not applicable (diasylate collected and 
analysed ex vivo)
Quantification Direct quantification of drug 
concentration15,24–26
Estimation of drug concentration 
calculated often using an internal standard 
method18–20
Resolution of sampling Up to 200 readings per second 
acquired in vivo
Samples are collected at timepoints 
(eg, every 15 min)
Laboratory analysis required No Yes, for both target and internal standard; 
often by use of HPLC techniques
HPLC=high-performance liquid chromatography.
Table 3: Comparison of the microneedle and microdialysis methods for extracellular drug monitoring
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